Shoddy production

Collier, Roger
March 2009
CMAJ: Canadian Medical Association Journal;3/3/2009, Vol. 180 Issue 5, p505
Academic Journal
The article reports that pharmaceutical company Actavis Inc. has been told by the U.S. Food and Drug Administration (FDA) that it can resume making and selling drugs when it meets "Good Manufacturing Practice" standards. Actavis was told by the FDA to close one of its plants because of the incorrect manufacturing of its heart drug Digitek. It was found that the company produced the drug twice as thick as its original size which could result to increased dosage.


Related Articles

  • Depression Update.  // PharmaWatch: CNS;Sep2010, Vol. 9 Issue 9, p10 

    The article offers news briefs on depression in the U.S. The Food and Drug Administration (FDA) has allowed Actavis Inc., a subsidiary of generic pharmaceutical company Actavis Group hf, to market Bupropion HCI extended-release (SR) tablets 100 milligram (mg) and 200 mg for the treatment of...

  • FDA WARNING LETTER ANALYSIS: A TOOL FOR GMP COMPLIANCE. Patel, Darshit S. // International Journal of Pharmaceutical Sciences & Research;Dec2012, Vol. 3 Issue 12, p4592 

    In the past few years, the US Food and Drug Administration has issued more warning letters, import alert & seizure to manufacturers of finished product for violation of the current good manufacturing practice regulation. Indian and US Pharmaceutical Manufacturer's Warning letter from the FDA's...

  • GMPs for Phase 1: Take 2. Bush, Laura // BioPharm International;Aug2008, Vol. 21 Issue 8, p10 

    The author reflects on the current good manufacturing practice (cGMP) required by the U.S. Food and Drug Administration (FDA) for clinical development. She states that FDA's recent decision to exempt most Phase 1 investigational drugs from complying with the regulatory cGMPs is not an excellent...

  • New GMP Documents from FDA.  // BioPharm International;Nov2004, Vol. 17 Issue 11, p10 

    The article focuses on the pharmaceutical current good manufacturing practice (cGMP) documents released by the U.S. Food & Drug Administration. The agency also issued four updated guidances related to the cGMP as applied to sterile drug products made by aseptic processing, quality systems,...

  • API GMP Warning Letter Update--Evolving Expectations and Basic Deficiencies. Lazar, Max // Journal of GXP Compliance;Spring2009, Vol. 13 Issue 2, p87 

    The article explores good manufacturing practice (GMP) violations cited in the warning letters of the U.S. Food and Drug Administration (FDA). It is stated that warning letters, which provide an indication of current GMP expectations of the FDA, are useful to help determine current areas of...

  • Electronic Signatures in a Regulated GMP Environment. McDowall, R. D. // Scientific Computing;Aug2012, Vol. 29 Issue 4, p4 

    In this article, the author discusses the electronic signatures in a regulated good manufacturing practice (GMP) environment. He mentions that release of the U.S. Food & Drug Administration (FDA) regulation for electronic records and signatures permitted the pharmaceutical industry to use...

  • FDA Withdraws Seven CMC and Stability Guidance Documents. McCormick, Douglas // Pharmaceutical Technology;Jul2006, Vol. 30 Issue 7, p18 

    The article offers information on the withdrawal of the United States Food and Drug Administration of seven guidance documents. This was a result of the realization that it was inconsistent with the agency's Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century (CGMP)...

  • Zone in on: REGULATION. Van Arnum, Patricia // Pharmaceutical Technology;Jan2008, Vol. 32 Issue 1, p20 

    The article reports on the rule established by the U.S. Food and Drug Administration (FDA) concerning the requirements for current good manufacturing practices (CGMPs) in pharmaceuticals laboratories. It states that the rule focuses on amending CGMPs regulations, including aseptic processing,...

  • Zone in on: Regulation.  // Pharmaceutical Technology;May2008, Vol. 32 Issue 5, p26 

    The article reports that the Food and Drug Administration in the U.S. withdrew a direct final rule that changed current good manufacturing practice (CGMP) regulations. The said withdrawal was executed because it received adverse comments from the industry. The rule was first published in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics